ProPhase Labs

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ProPhase Labs achieves record revenues, Nebula Genomics poised for growth

ProPhase Labs delivered strong financial performance in 2022, showcasing a successful transformation and diversification strategy.
The company's subsidiaries, particularly Nebula Genomics and BE-Smart, offer significant growth potential and differentiation in their respective markets.
While challenges like declining COVID testing trends and financial impacts exist, strategic opportunities and efficient management position ProPhase Labs for continued success.

ProPhase Labs prioritizes value-building over earnings, eyes global growth

ProPhase Labs is strategically focusing on long-term value creation through its diverse business segments.
While facing challenges in COVID testing and profitability, the company is optimistic about revenue growth from key assets.
Opportunities in precision medicine, cancer compounds, and global expansion present avenues for future growth.

ProPhase Labs shifts focus to genetic testing, eyes global expansion

ProPhase Labs is strategically pivoting towards genetic testing with Nebula Genomics, focusing on advanced laboratory capabilities and potential revenue generation. Despite revenue declines in Q2, the company remains optimistic about future growth prospects and is actively exploring financing options for expansion.

ProPhase Labs anticipates substantial growth with innovative healthcare solutions

ProPhase Labs is strategically positioned for growth with strong demand for its subsidiaries and innovative healthcare solutions in development.
While facing challenges in market conditions and revenue guidance, the company's focus on expansion and efficiency drives optimism for future performance.
Opportunities lie in revenue and profitability increases, potential IPOs, and advancements in esophageal cancer testing techniques and therapeutics.
Investors are encouraged to consider the long-term potential of ProPhase Labs as it navigates challenges and capitalizes on growth prospects.

ProPhase Labs excels in Q4, eyes revenue growth and strategic partnerships

ProPhase Labs showcased strong historical performance, profitable business segments, and strategic growth initiatives. The company is poised for substantial revenue growth through key contracts, innovative product offerings, and expansion into new markets. Challenges in short-term profitability and regulatory restrictions are being addressed while focusing on long-term value creation and growth potential.

ProPhase Labs (PRPH) reports strong performance and explores strategic opportunities

ProPhase Labs (PRPH) showcased strong historical performance, highlighted key initiatives like Pharmaloz and Nebula Genomics, and emphasized the potential for liquidity events. Challenges include revenue growth uncertainty and transparency concerns over share count increase.

ProPhase Labs strategizes for growth amidst seasonality and liquidity concerns

ProPhase Labs is navigating mixed performance with a focus on strategic initiatives, liquidity management, and maximizing shareholder value.
The company's strengths lie in its leadership team, growth potential in precision medicine, and plans for mitigating seasonality in revenue streams.
Challenges include seasonality impact, liquidity concerns, and the need for successful execution of strategic alternatives for Pharmaloz.
Opportunities exist in partnerships for Pharmaloz, growth potential in precision medicine, and anticipated revenue growth in the upcoming quarters.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation.

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

Lantern Pharma

Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.

ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2022 Earnings Conference Call November 10, 2022 11:00 AM ET Company Participants Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Fred McDonald – Private Investor Yi Chen – H.C. Wainwright Dennis Waldman – Barrett Productions, LLC Patrick Patterson – Investor Operator Good morning, afternoon, evening, and welcome to the ProPhase Labs Third Quarter 2022 Financial Results Conference Call.

ProPhase Labs, Inc. (PRPH) Q3 2022 Earnings Call Transcript

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates

GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in the Q4 Investor Summit Conference, which will take place on November 14, 2022 in New York, New York. ProPhase Labs' CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 3:00 PM ET on November 14, 2022.

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

GARDEN CITY, NY, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, November 10, 2022 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time

Assertio Therapeutics Inc

Verona Pharma

This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.

3 Small-Cap Pharma Stocks For A 2022 Melt-Up

GARDEN CITY, NY, Oct. 17, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth-oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc., has added Russ B. Altman, M.D., Ph.D to its Advisory Board. Dr. Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and Computer Science, and past chair of the Bioengineering Department at Stanford University. Dr. Altman is the second member of Nebula's Advisory Board and joins Dr. George Church, Nebula's Founder and Advisory Board Chairman. Nebula Genomics, a global leader in direct-to-consumer whole genome sequencing, has achieved significant year over year growth. Dr. Altman's expertise will support continued expansion through thought leadership, industry knowledge and strategic guidance.

Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.

ProPhase Labs released record breaking Q2 2022 results beating earnings expectations by $0.22 with EPS of $0.40. ProPhase Labs has surpassed earning expectations for the last three consecutive quarters.

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

Ashford Hospitality Trust

BankFinancial

Consolidated Water

ContextLogic Inc

A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.

5 Big Winners as Dollar Strengthens on Fed Rate Hike

Here is how ProPhase Labs, Inc. (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?

GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

Does ProPhase Labs, Inc. (PRPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why ProPhase Labs, Inc. (PRPH) is a Great Momentum Stock to Buy

ProPhase Labs, Inc (NASDAQ:PRPH ) Q2 2022 Earnings Conference Call August 11, 2022 9:00 AM ET Company Participants Ted Karkus - Chairman & Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Dennis Waldman - Barrett Productions, LLC Operator Good morning, and welcome to the ProPhase Labs Second Quarter 2022 Financial Results and Corporate Update.

ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q2 2022 Results - Earnings Call Transcript

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 233.33% and 28.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Tops Q2 Earnings and Revenue Estimates

GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?

ProPhase Labs has expanded its in-house testing capabilities for the diagnostics of the new clinical chemistry, immunoassay, hematology, hemostasis, and urinalysis analyzers. ProPhase Labs has successfully obtained rights to commercialize two patented small molecule PIM kinase inhibitors in the licensing agreement with Global BioLife, Inc.

ProPhase Labs: A Growth Stock At An Attractive Valuation

Confirms Quarterly Growth continues year-over-year

ProPhase Labs Announces Licensing of New Investigational Cancer Compounds

Chefs' Warehouse

Daqo New Energy

Franklin Covey

USA Truck

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are USAK, FC, PRPH, DQ and CHEF.

5 Stocks With Recent Price Strength for a Steady Portfolio

ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?

ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ProPhase Labs, Inc. (PRPH) Upgraded to Strong Buy: Here's What You Should Know

100% technical buy signals. 12 new highs and up 53.07% in the last month.

ProPhase Labs: Healthcare Done Right

Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds Equivir and Equivir G

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology

ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for ProPhase Labs Stock (PRPH)